{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-200078","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.518572+00:00","generated_at":"2026-05-17T07:00:39.917394+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned","bullets":["2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.","1L monotherapy (300 mg): ORR 47%, DCR 89% among 38 evaluable patients as of July 28, 2025 cutoff.","1L combo daraxonrasib 200 mg + gemcitabine/nab-paclitaxel: ORR 55%, DCR 90% in 31 evaluable patients.","Grade ≥3 TRAEs: 34% monotherapy (2L), 35% (1L), 58% combo; most common rash, GI; 0% discontinuation in 2L.","Company plans to initiate RASolute 303, a global Phase 3 trial in 1L PDAC comparing daraxonrasib ± GnP vs GnP."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-200078","json":"https://secwatch.observer/filing/0001193125-25-200078.json","markdown":"https://secwatch.observer/filing/0001193125-25-200078.md","text":"https://secwatch.observer/filing/0001193125-25-200078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/0001193125-25-200078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525200078/d947102d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:00:39.917394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}